Supplementary Material for:

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

Raffit Hassan,* Andrew C. Miller, Elad Sharon, Anish Thomas, James C. Reynolds, Alexander Ling, Robert J. Kreitman, Markku M. Miettinen, Seth M. Steinberg, Daniel H. Fowler, Ira Pastan

*Corresponding author. E-mail: hassanr@mail.nih.gov

Published 23 October 2013, Sci. Transl. Med. 5, 208ra147 (2013)
DOI: 10.1126/scitranslmed.3006941

This PDF file includes:

• Table S1. Previous therapies received by patients.
• Table S2. Adverse events related to SS1P, pentostatin, or cyclophosphamide.
• Table S3. Association of NLR and PLR with tumor response.

[Download PDF]